Identification of a Three-Biomarker Panel in Urine for Early Detection of Pancreatic Adenocarcinoma

A migration signature and plasma biomarker panel for pancreatic adenocarcinoma.

Pancreatic ductal adenocarcinoma is a disease of extremely poor prognosis for which there are no reliable markers of asymptomatic disease. To identify pancreatic cancer biomarkers, we focused on a genomic interval proximal to the most common fragile site in the human genome, chromosome 3p12, which undergoes smoking-related breakage, loss of heterozygosity, and homozygous deletion as an early ev...

Identification and Validation of a Diagnostic and Prognostic Multi-Gene Biomarker Panel for Pancreatic Ductal Adenocarcinoma

Citation: Klett H, Fuellgraf H, Levit-Zerdoun E, Hussung S, Kowar S, Küsters S, Bronsert P, Werner M, Wittel U, Fritsch R, Busch H and Boerries M (2018) Identification and Validation of a Diagnostic and Prognostic Multi-Gene Biomarker Panel for Pancreatic Ductal Adenocarcinoma. Front. Genet. 9:108. doi: 10.3389/fgene.2018.00108 Identification and Validation of a Diagnostic and Prognostic Multi-...

PAM4-reactive MUC1 is a biomarker for early pancreatic adenocarcinoma.

PURPOSE The anti-MUC1 monoclonal antibody (MAb), PAM4, has a high specificity for pancreatic adenocarcinoma compared with other cancers, normal tissues, or pancreatitis. In order to assess its role in early pancreatic cancer development, we examined the expression of the PAM4-reactive MUC1 in the noninvasive precursor lesions, pancreatic intraepithelial neoplasia (PanIN) and intraductal papilla...

Identification of A Panel of Serum microRNAs as Biomarkers for Early Detection of Lung Adenocarcinoma

Introduction: Since currently no sensitive and specific biomarkers for early detection of lung adenocarcinoma (AD) exist and the majority of AD patients are diagnosed at late stages of disease, the development of effective screening tests for early-stage lung AD is urgently needed. Serum microRNAs (miRNAs) have been documented as novel noninvasive biomarkers in tumor diagnosis; thus, we studied...

Pancreatic Adenocarcinoma NCCN Pancreatic Adenocarcinoma Panel Members